Fig. 3From: Baseline soluble MICA levels act as a predictive biomarker for the efficacy of regorafenib treatment in colorectal cancersMICA levels in CRC patients compared between responders and non-responders. A sMICA levels were compared between responders (N = 8) and non-responders (N = 9), before and (B) 48 h after regorafenib therapy. *P < 0.05. well-dif: well-differentiatedBack to article page